Astria Therapeutics Inc
ATXS6.855USD
+0.295+4.50%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
386.86MCap. mercado
PérdidaP/E TTM
Más Datos de Astria Therapeutics Inc Compañía
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Información de la empresa
Símbolo de cotizaciónATXS
Nombre de la empresaAstria Therapeutics Inc
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoDr. Jill C. Milne, Ph.D.
Número de empleados78
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección22 Boston Wharf Road
CiudadBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02210
Teléfono16173491971
Sitio Webhttps://astriatx.com/
Símbolo de cotizaciónATXS
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoDr. Jill C. Milne, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
32.69%
Venture Capital
23.81%
Hedge Fund
19.93%
Investment Advisor/Hedge Fund
16.86%
Private Equity
11.49%
Research Firm
1.00%
Individual Investor
0.49%
Pension Fund
0.21%
Bank and Trust
0.19%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
263
60.20M
106.68%
-10.73M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
RA Capital Management, LP
5.11M
9.05%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.86%
ALPS Medical Breakthroughs ETF
Proporción0.2%
iShares Micro-Cap ETF
Proporción0.05%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
iShares Biotechnology ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Fecha
Tipo
Relación
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
